FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381838345> ?p ?o ?g. }

• W4381838345 endingPage "133" @default.
• W4381838345 startingPage "126" @default.
• W4381838345 abstract "The study was made to evaluate the effect of interleukin-2 (IL-2) as part of the R-CHOP regimen on the rate of a complete metabolic response (CMR) using the data of interim positron emission tomography (PET/CT) and progression-free survival compared to the standard regimen in patients with diffuse B-cell lymphoma (DCLC). The data of 152 patients with biopsy-proven DCLC who were treated in the period 2015–2020 were included. Among them, 59 patients were included in the prospective group (R-CHOP + IL-2 in a total course dose of 5,000,000 IU). The control group consisting of 93 patients received standard R-CHOP therapy. PET/CT was performed after 4 courses of therapy, metabolic response was assessed using the Deauville scale, and Deauville 1-2 was classified as CMR. The rate of CMR in the R-CHOP+IL-2 group was 67.8 %, while in the control group it was 50.5 % (pχ² = 0.044). The 5-year progression-free survival (PFS) in the R-CHOP+IL-2 and R-CHOP groups was 80.7 and 64.5 %, respectively (p = 0.04). In the favorable and intermediate prognosis groups (IPI 0–3), PFS was not statistically significantly different depending on treatment. At high risk (IPI 4–5), the 5-year PFS in the R-CHOP + IL-2 and R-CHOP groups was 71.4 and 25.0 %, respectively (p = 0.02). Including IL-2 in the R-CHOP regimen in the first-line treatment of patients with DCLC increases the incidence of CMR according to 18-FDG PET/CT after 4 courses of chemoimmunotherapy and PFS in the high-risk group." @default.
• W4381838345 created "2023-06-25" @default.
• W4381838345 creator A5005514277 @default.
• W4381838345 creator A5028201586 @default.
• W4381838345 creator A5066652574 @default.
• W4381838345 creator A5086859649 @default.
• W4381838345 date "2023-05-07" @default.
• W4381838345 modified "2023-10-18" @default.
• W4381838345 title "Results of R-CHOP and R-CHOP + interleukin-2 regimens in first-line therapy in patients with diffuse B-cell lymphoma" @default.
• W4381838345 cites W1914229355 @default.
• W4381838345 cites W2063157305 @default.
• W4381838345 cites W2063792914 @default.
• W4381838345 cites W2106928992 @default.
• W4381838345 cites W2112519281 @default.
• W4381838345 cites W2129664415 @default.
• W4381838345 cites W2145453495 @default.
• W4381838345 cites W2162693374 @default.
• W4381838345 cites W2167556523 @default.
• W4381838345 cites W2744261860 @default.
• W4381838345 cites W3134205746 @default.
• W4381838345 cites W3159095190 @default.
• W4381838345 cites W3204660098 @default.
• W4381838345 cites W4205736005 @default.
• W4381838345 doi "https://doi.org/10.29235/1561-8323-2023-67-2-126-133" @default.
• W4381838345 hasPublicationYear "2023" @default.
• W4381838345 type Work @default.
• W4381838345 citedByCount "0" @default.
• W4381838345 crossrefType "journal-article" @default.
• W4381838345 hasAuthorship W4381838345A5005514277 @default.
• W4381838345 hasAuthorship W4381838345A5028201586 @default.
• W4381838345 hasAuthorship W4381838345A5066652574 @default.
• W4381838345 hasAuthorship W4381838345A5086859649 @default.
• W4381838345 hasBestOaLocation W43818383451 @default.
• W4381838345 hasConcept C126322002 @default.
• W4381838345 hasConcept C143998085 @default.
• W4381838345 hasConcept C2778559949 @default.
• W4381838345 hasConcept C2779338263 @default.
• W4381838345 hasConcept C2779725641 @default.
• W4381838345 hasConcept C2780653079 @default.
• W4381838345 hasConcept C2781413609 @default.
• W4381838345 hasConcept C2989005 @default.
• W4381838345 hasConcept C71924100 @default.
• W4381838345 hasConcept C90924648 @default.
• W4381838345 hasConceptScore W4381838345C126322002 @default.
• W4381838345 hasConceptScore W4381838345C143998085 @default.
• W4381838345 hasConceptScore W4381838345C2778559949 @default.
• W4381838345 hasConceptScore W4381838345C2779338263 @default.
• W4381838345 hasConceptScore W4381838345C2779725641 @default.
• W4381838345 hasConceptScore W4381838345C2780653079 @default.
• W4381838345 hasConceptScore W4381838345C2781413609 @default.
• W4381838345 hasConceptScore W4381838345C2989005 @default.
• W4381838345 hasConceptScore W4381838345C71924100 @default.
• W4381838345 hasConceptScore W4381838345C90924648 @default.
• W4381838345 hasIssue "2" @default.
• W4381838345 hasLocation W43818383451 @default.
• W4381838345 hasOpenAccess W4381838345 @default.
• W4381838345 hasPrimaryLocation W43818383451 @default.
• W4381838345 hasRelatedWork W2063044228 @default.
• W4381838345 hasRelatedWork W2110119190 @default.
• W4381838345 hasRelatedWork W2114390896 @default.
• W4381838345 hasRelatedWork W2185755944 @default.
• W4381838345 hasRelatedWork W2390430401 @default.
• W4381838345 hasRelatedWork W2392293741 @default.
• W4381838345 hasRelatedWork W2393400362 @default.
• W4381838345 hasRelatedWork W2915014687 @default.
• W4381838345 hasRelatedWork W2980299611 @default.
• W4381838345 hasRelatedWork W3031860663 @default.
• W4381838345 hasVolume "67" @default.
• W4381838345 isParatext "false" @default.
• W4381838345 isRetracted "false" @default.
• W4381838345 workType "article" @default.